Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Glecaprevir/Pibrentasvir Tx in Renal & CV Outcomes

Infect Dis Ther; ePub 2018 Oct 27; Tran, et al

In patients with chronic hepatitis C (CHC) without cirrhosis, short-duration treatment with glecaprevir/pibrentasvir (G/P) resulted in stable renal function and improvements in cardiovascular (CV) and metabolic extrahepatic manifestation (EHM) markers, especially in those with severe EHMs at baseline. This according to a post-hoc analysis of 2 phase 3 clinical trials in patients without cirrhosis treated with G/P for 8 weeks. In addition, 1 phase 3 trial was carried out to explore the effects of treatment on renal EHMs in patients with advanced renal impairment at baseline. Researchers included all CHC patients treated with G/P for 8 or 12 weeks enrolled across 5, phase 3 trials as a sensitivity analysis. They found:

  • G/P treatment for 8 weeks resulted in statistically significant declines in triglycerides (‒28.6 mg/dL) and glucose (‒11.2 mg/dL), with no statistically significant decline in estimated glomerular filtration rate (eGFR).
  • Biomarker improvements were greatest among patients with elevated triglycerides and elevated glucose at baseline.
  • Similar effects were observed across all patients treated with G/P for 8 or 12 weeks.


Tran TT, Mehta D, Mensa F, Park C, Bao Y, Sanchez Gonzalez Y. Pan-genotypic hepatitis C treatment with glecaprevir and pibrentasvir for 8 weeks resulted in improved cardiovascular and metabolic outcomes and stable renal function: A post-hoc analysis of phase 3 clinical trials. [Published online ahead of print October 27, 2018]. Infect Dis Ther. doi:10.1007/s40121-018-0218-x.